• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:朱立平,魏绪霞,郝丽娜,薛宁,李霞.英夫利西单抗治疗儿童溃疡性结肠炎的疗效及安全性[J].药学研究,2024,43(5):504-508[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2908次   下载 2676次 本文二维码信息
码上扫一扫!
英夫利西单抗治疗儿童溃疡性结肠炎的疗效及安全性
朱立平1,魏绪霞1,郝丽娜1,薛宁1,李霞2
字体:加大+|默认|缩小-
(1.济南市儿童医院,山东 济南 250022;2.山东省药品不良反应监测中心,山东 济南 250014)
摘要:
目的 评价英夫利西单抗(infliximab,IFX)治疗儿童溃疡性结肠炎(ulcerative colitis,UC)的疗效以及安全性。方法 回顾性分析2018年1月至2022年12月在济南市儿童医院接受IFX治疗的21例溃疡性结肠炎患儿临床资料。比较治疗前后儿童UC疾病活动指数(pediatric ulcerative colitis activity index,PUCAI)、内镜严重程度评分和实验室检查结果,评估IFX疗效及安全性。结果 21例UC患儿中男12例、女9例。IFX疗效分析显示,第14周诱导缓解期临床应答率76.2%(16/21),临床缓解率66.7%(14/21)。第30周维持缓解期临床应答率76.4%(13/17),持续缓解率58.5%(10/17)。与治疗前相比,IFX治疗第14周及30周PUCAI、C反应蛋白(C reactive protein,CRP)、红细胞沉降率(erythrocyte sedimentation rate,ESR)、粪便钙卫蛋白均明显下降(P<0.05),血红蛋白、白蛋白均有显著改善(P<0.05)。14周复查结肠镜,8例达到黏膜愈合,6例由重度炎症减轻为中度炎症,4例黏膜炎症中度炎症减轻为轻度炎症,2例黏膜炎症无好转。IFX输液反应发生率为 43%(9/21),包括急性输液反应、迟发性输液反应、转氨酶升高,其中治疗期间感染最常见,发生率为38%(8/21)。结论 IFX对儿童UC疗效显著,但治疗期间需警惕不良事件的发生。
关键词:  英夫利西单抗  儿童  溃疡性结肠炎  疗效  不良反应
DOI:10.13506/j.cnki.jpr.2024.05.015
基金项目:山东省药品化妆品不良反应监测哨点课题(No.2022SDADRKY02)
出版日期:2024-05-25
Efficacy and safety of infliximab in the treatment of ulcerative colitis in children
ZHU Liping1,WEI Xuxia1,HAO Lina1,XUE Ning1,LI Xia2
(1.Department of Jinan Children's Hospital,Jinan 250022,China;2.Department of Shandong Provincial Adverse Center for ADR Monitoring,Jinan 250014,China)
Abstract:
Objective To evaluate the efficacy and safety of infliximab (IFX) in children with ulcerative colitis (UC). Methods The clinical data of 21 children with ulcerative colitis who received IFX at Jinan Children's Hospital from January 2018 to December 2022 were analyzed retrospectively.The pediatric ulcerative colitis activity index(PUCAI)、ulcerative colitis endoscopic index of severity and laboratory findings were compared to assess the efficacy and safety of IFX. Results There were 12 males and 9 females among 21 children with UC. IFX efficacy analysis showed that the clinical response rate at week 14 was 76.2% (16/21) and the clinical response rate was 66.7% (14/21). The clinical response rate in maintained remission at week 30 was 76.4% (13/17) and the sustained response rate was 58.5% (10/17). PUCAI score, C reactive protein, erythrocyte sedimentation rate and fecal calprotectin were significantly decreased in 14 and 30 weeks of IFX treatment compared with before treatment (P<0.05), and hemoglobin and albumin were significantly improved (P<0.05). At 14 weeks,8 cases achieved mucosal healing,6 cases reduced severe mucosal inflammation to moderate inflammation, 4 cases reduced moderate inflammation to mild inflammation, and 2 cases showed no improvement in mucosal inflammation.The incidence of IFX infusion reactions was 43%(9/21),including acute infusion reactions,delayed infusion reactions,and transaminase elevation.Infections were the most common during treatment, with an incidence of 38% (8/21).Conclusion IFX is effective on UC in children, However, we should be alert to the occurrence of adverse events during the treatment.
Key words:  Infliximab  Children  Ulcerative colitis  Efficacy  Adverse effects
今日访问量:2656    总访问量:55339172
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司